A study of a new sub-cutaneous formulation of Actemra/RoActemra in children with systemic juvenile idiopathic arthritis

Registry ID

EUCTR2012-003490-26

Source registry

EUCTR

Status

Completed

Phase

PHASE1

Sponsor

F. Hoffmann-La Roche Ltd

Start date

2013-06-14

Completion date

2017-06-15

Last update

2026-08-16

Conditions

• Systemic Juvenile Idiopathic Arthritis (sJIA)

Summary

Primary Objective - To characterize the pharmacokinetics of subcutaneous tocilizumab (SC TCZ) in patients with sJIA - To evaluate the pharmacodynamics of SC TCZ in patients with sJIA - To evaluate the safety of SC TCZ in patients with sJIA

Locations

• , , Italy
• , , UK
• , , Spain
• , , Germany

Related clinical trials

• Ilaris NIS in Korea
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

View on source registry